HIF Inhibitors: New Hope for Cancer Therapy
Tejraj M. Aminabhavi,
Malleshappa N. Noolvi.
Cancer remains a critical study since long period. Inspite of remarkable
development in science, still suitable cure and treatment is not available. In humans,
Hypoxia-inducible factor-1 (HIF-1) is available in good amount in tumors and is associated
in various mechanisms such as metabolism of anaerobic energy, angiogenesis, drug resistance, cell subsistence and
incursion etc. Hence, for the treatment of cancer, HIF-1 inhibition may be considered as an obvious strategy. Recent studies
illustrate many advances in cancer biology and biotechnology for targeting new HIF-1 agents. Numerous heterocyclic
compounds are available as anticancer agents and countless struggles have been placed to discover unique agents in the
coming years, which can be considered as an important tool for the diagnosis of cancer. This review provides a vision for
novel anticancer targets and highlights rationally designed drugs in clinical advancement, and also the budding molecules
that can influence clinical care in the coming future. Although several anticancer treatments have been familiarized in the
recent years, however, none of them stand up for a better cure and because of which a new and advanced treatment
Keywords: Anticancer agents, cancer, heterocyclic compounds, HIF, synthesis, treatment.
Rights & PermissionsPrintExport